Positives

• Charite-treated post-COVID ME/CFS patients with elevated beta-2 AR autoantibodies reported significant relief from fatigue, pain, cognitive and autonomic symptoms within four weeks, lasting up to six months Lancet Regional Health Europe.
  
  
• The five-session protocol was generally well tolerated, dropping total IgG by 79% and beta-2 AR-AB by 77% ME Association.
  
  

Negatives

• A subset of treated patients did not respond, suggesting autoantibodies may drive only one LC subgroup ME Association.
  
  
• Benefits faded over months in some patients, requiring repeat cycles to maintain response PubMed.
  
  

Hurdles & Side Effects

• The trial had no placebo arm, so results need cautious interpretation before broader rollout ME Association.
  
  
• The procedure requires specialized apheresis columns and is currently offered at very few centers, mostly in Germany MDPI.